Stellar Biotechnologies Inc (SBOT)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013410)
◆英語タイトル:Stellar Biotechnologies Inc (SBOT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013410
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:44
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injectable product to assess immune response. Its products comprise Stellar KLH protein which can be used in various grades, formulations, and configurations for both clinical and research applications and KLH Elisa Kits. Stellar Bio’s products are used in immunotherapies as an immune stimulant in immunotoxicology applications and therapeutic vaccine conjugation. The company partners with research centers and developers of active immunotherapies and therapeutic vaccines. Stellar Bio is headquartered in Port Hueneme, California, the US.

Stellar Biotechnologies Inc (SBOT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2011 to YTD 2017 10
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Stellar Biotech and Neovacs Form Joint Venture 12
Stellar Biotech Enters Into Co-Development Agreement With Amaran Biotech 13
Stellar Biotechnologies Announces Co-Development Agreement With A Biotech Company 14
Stellar Biotechnologies Enters Into Co-Marketing Agreement With SAFC 15
Equity Offering 16
Stellar Biotech Raises USD6.8 Million in Private Placement of Shares and Warrants 16
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 17
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 19
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 21
Stellar Biotech Completes Private Placement Of Units For US$0.5 Million 22
Stellar Biotechnologies Completes Private Placement Of Units For US$1 Million 23
Asset Transactions 24
Matrivax to Acquire Immunogen and Vaccine Technology from Stellar Biotech 24
Stellar Biotechnologies Inc – Key Competitors 25
Stellar Biotechnologies Inc – Key Employees 26
Stellar Biotechnologies Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 27
Recent Developments 28
Financial Announcements 28
Aug 09, 2017: Stellar Biotechnologies Reports Third Quarter 2017 Financial Results 28
May 09, 2017: Stellar Biotechnologies Reports Second Quarter 2017 Financial Results 30
Feb 06, 2017: Stellar Biotechnologies Reports First Quarter 2017 Financial Results 32
Dec 14, 2016: Stellar Biotechnologies Reports Fiscal Year 2016 Financial Results 33
Aug 09, 2016: Stellar Biotechnologies Reports Third Quarter 2016 Financial Results and Operational Highlights 34
May 09, 2016: Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights 36
Feb 08, 2016: Stellar Biotechnologies Reports First Quarter 2016 Financial Results and Operational Highlights 37
Corporate Communications 38
Dec 09, 2016: Stellar Biotechnologies appoints two new board members 38
Dec 09, 2016: Stellar Biotechnologies Appoints Pharma and Capital Markets Experts to Board of Directors 39
Jul 19, 2016: Neovacs and Stellar Biotechnologies Announce changes of Administrative Board and Management Team 40
Mar 29, 2016: Stellar Biotechnologies’ Announces Effective Date of TSX-V Voluntary Delisting 41
Mar 23, 2016: Stellar Biotechnologies Applies for Voluntary Delisting From TSX Venture Exchange 42
Product News 43
Jan 11, 2017: Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Stellar Biotechnologies Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Stellar Biotechnologies Inc, Medical Devices Deals, 2011 to YTD 2017 10
Stellar Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Stellar Biotech and Neovacs Form Joint Venture 12
Stellar Biotech Enters Into Co-Development Agreement With Amaran Biotech 13
Stellar Biotechnologies Announces Co-Development Agreement With A Biotech Company 14
Stellar Biotechnologies Enters Into Co-Marketing Agreement With SAFC 15
Stellar Biotech Raises USD6.8 Million in Private Placement of Shares and Warrants 16
Stellar Biotechnologies Completes Second Tranche Private Placement Of Units For US$12 Million 17
Stellar Biotechnologies Completes Second Tranche Of Private Placement Of Units For US$5 Million 19
Stellar Biotechnologies Completes Private Placement Of Units For US$1.6 Million 21
Stellar Biotech Completes Private Placement Of Units For US$0.5 Million 22
Stellar Biotechnologies Completes Private Placement Of Units For US$1 Million 23
Matrivax to Acquire Immunogen and Vaccine Technology from Stellar Biotech 24
Stellar Biotechnologies Inc, Key Competitors 25
Stellar Biotechnologies Inc, Key Employees 26
Stellar Biotechnologies Inc, Joint Venture 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Stellar Biotechnologies Inc (SBOT)-製薬・医療分野:企業M&A・提携分析(Stellar Biotechnologies Inc (SBOT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆